GSK Formula For Older Products: "Clever" Patent Defenses, Cutting SKUs
Executive Summary
GlaxoSmithKline's next phase of global streamlining will focus on reducing the number of formulations of older brands that it produces.
You may also be interested in...
SmithKline Paxil patents
FTC has opened an investigation "to determine whether SmithKline has engaged in unfair methods of competition...by preventing or impeding competition to Paxil from generic paroxetine," Apotex/Torpharm discloses in Dec. 5 court filing. The companies are in litigation over "late-listed" patents (1"The Pink Sheet" Dec. 4, p. 25)
SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate
SmithKline Beecham could face competition to its antidepressant Paxil in the U.S. from an NDAed version of a different salt of paroxetine filed by Synthon.
SB Augmentin Composition Patent May Protect U.S. Sales Until 2017
A formulation patent issued for SmithKline Beecham's flagship antibiotic Augmentin may protect the U.S. market for the product until 2017.